No Data
Xiangxue Pharmaceutical (300147.SZ): A projected loss of 0.5996 billion yuan to -0.8624 billion yuan for the year 2024.
On January 15, Gu Longhui reported that Xiangxue Pharmaceutical (300147.SZ) announced its performance forecast for 2024. The net income attributable to shareholders of the listed company is expected to be a loss of 0.5996 billion to 0.8624 billion yuan, compared to a loss of 388.96 million yuan in the same period last year. The net income after deducting non-recurring gains and losses is expected to be a loss of 0.571 billion to 0.834 billion yuan, compared to a loss of 344.46 million yuan in the same period last year. The revenue is expected to be 1.613 billion to 2.013 billion yuan, while the revenue after deductions is expected to be 1.586 billion to 1.986 billion yuan. In 2024, the company will focus on its development strategy and annual operational goals through
Xiangxue Pharmaceuticals: 2024 Annual Results Forecast
More Unpleasant Surprises Could Be In Store For Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) Shares After Tumbling 28%
Investors Ignore Increasing Losses at Xiangxue PharmaceuticalLtd (SZSE:300147) as Stock Jumps 5.0% This Past Week
Xiangxue Pharmaceutical (300147.SZ): TAEST16001 injection is currently in Phase II clinical stage.
Gelonghui November 6th | xiangxue pharmaceutical (300147.SZ) stated on the investor interaction platform that TAEST16001 injection is currently in Phase II clinical stage. The progress of research and development will be disclosed to the public in the form of announcements based on clinical situations combined with information disclosure rules.
Revenues Not Telling The Story For Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) After Shares Rise 101%
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) 29% Dip In Price Shows Sentiment Is Matching Revenues
No Data
